Réalisation d’un programme de chimie médicinale « hit-to-lead » pour le développement de composés chimiques jouant le rôle de modulateur allostérique d’une kinase identifiée comme cible thérapeutique

This tender concerns a medicinal chemistry hit-to-lead programme aimed at developing chemical compounds that act as allosteric modulators of a kinase identified as a therapeutic target. The successful supplier will conduct research and development to advance promising lead compounds through preclinical stages.

Suppliers must have expertise in medicinal chemistry, particularly in hit-to-lead optimization, allosteric modulator design, and kinase biology. Demonstrated experience with compound synthesis, characterization, and preclinical evaluation is required.

This tender is suitable for specialized pharmaceutical research companies, contract research organizations (CROs), or academic research institutions with strong capabilities in medicinal chemistry and kinase modulation.

The buyer is ERGANEO.

Submissions close on June 13, 2026.